Adverse drug reaction prediction using scores produced by large-scale drug-protein target docking on high-performance computing machines

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Labute, Montiago X ^a   Zhang, Xiaohua ^a   Lenderman, Jason ^a   Bennion, Brian J ^a   Wong, Sergio E ^a   Lightstone, Felice C ^a  

^a LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; CASPASE 3; CD18 ANTIGEN; COMPLEMENT COMPONENT C3; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERSTITIAL COLLAGENASE; PROFILIN; PROFILIN 1; PROTEIN KINASE SYK; UNCLASSIFIED DRUG; DRUG; PROTEIN;

ANEURYSM; ARTICLE; DATA MINING; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; LOGISTIC REGRESSION ANALYSIS; MEDICAL INFORMATION SYSTEM; MOLECULAR DOCKING; NEOPLASM; PREDICTION; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; VALIDATION PROCESS; ADVERSE DRUG REACTION; ALGORITHM; CHEMISTRY; COMPUTER SIMULATION; HUMAN; INFORMATION PROCESSING; METABOLISM; PROCEDURES;

ALGORITHMS; COMPUTER SIMULATION; DATA MINING; DATASETS AS TOPIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MOLECULAR DOCKING SIMULATION; PHARMACEUTICAL PREPARATIONS; PROTEINS;

EID: 84906997312     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106298     Document Type: Article

References (87)

1. Giacomini KM, Krauss RM, Roden DM, Eichelbaum M, Hayden MR, et al. (2007) When good drugs go bad. Nature 446: 975-977.
2. Ernst FR, Grizzle AJ (2001) Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) 41: 192-199.
3. Herman WH (2013) The Economic Costs of Diabetes: Is It Time for a New Treatment Paradigm? Diabetes Care 36: 775-776.
4. Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, et al. (2010) Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 31: 824-831.
5. Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, et al. (2008) Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 372: 1756-1764.
6. Bowes J, Brown AJ, Hamon J, Jarolimek W, Sridhar A, et al. (2012) Reducing safety-related drug attrition: The use of in vitro pharmacological profiling. Nat Rev Drug Discov 11: 909-922.
7. Whitebread S, Hamon J, Bojanic D, Urban L (2005) Keynote review: In vitro safety pharmacology profiling: An essential tool for successful drug development. Drug Discovery Today 10: 1421-1433.
8. Fliri AF, Loging WT, Thadeio PF, Volkmann RA (2005) Analysis of druginduced effect patterns to link structure and side effects of medicines. Nat Chem Biol 1: 389-397.
9. Cobanoglu MC, Liu C, Hu F, Oltvai ZN, Bahar I (2013) Predicting Drug- Target Interactions Using Probabilistic Matrix Factorization. Journal of Chemical Information and Modeling 53: 3399-3409.
10. Campillos M, Kuhn M, Gavin A-C, Jensen LJ, Bork P (2008) Drug Target Identification Using Side-Effect Similarity. Science 321: 263-266.
11. Pauwels E, Stoven V, Yamanishi Y (2011) Predicting drug side-effect profiles: A chemical fragment-based approach. BMC Bioinformatics 12: 169.
12. Bolton EE, Wang Y, Thiessen PA, Bryant SH (2008) Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities. Annual Reports in Computational Chemistry 4:217-241.
13. Yamanishi Y, Pauwels E, Kotera M (2012) Drug side-effect prediction based on the integration of chemical and biological spaces. J Chem Inf Model 52: 3284- 3292.
14. Liu M, Wu Y, Chen Y, Sun J, Zhao Z, et al. (2012) Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. Journal of the American Medical Informatics Association 19: e28-e35.
15. Cami A, Arnold A, Manzi S, Reis B (2011) Predicting Adverse Drug Events Using Pharmacological Network Models. Science Translational Medicine 3: 114-127.
16. Mizutani S, Pauwels E, Stoven V, Goto S, Yamanishi Y (2012) Relating drugprotein interaction network with drug side effects. Bioinformatics 28: i522-i528.
17. Gunther S, Kuhn M, Dunkel M, Campillos M, Senger C, et al. (2008) Super Target and Matador: resources for exploring drug-target relationships. Nucleic Acids Res 36: D919-D922.
18. Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P (2010) A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 6: 343.
19. Kanehisa M (2002) The KEGG database. Novartis Found Symp 247: 91-101; discussion 101-103, 119-128, 244-152.
20. Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, et al. (2004) The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res 32: D258- D261.
21. Kuhn M, Al Banchaabouchi M, Campillos M, Jensen LJ, Gross C, et al. (2013) Systematic identification of proteins that elicit drug side effects. Mol Syst Biol 9: 663.
22. Tatonetti NP, Liu T, Altman RB (2009) Predicting drug side-effects by chemical systems biology. Genome Biol 10: 238.
23. Scheiber J, Chen B, Milik M, Sukuru SCK, Bender A, et al. (2009) Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis. Journal of Chemical Information and Modeling 49: 308-317.
24. Huang LC, Wu X, Chen JY (2011) Predicting adverse side effects of drugs. BMC Genomics 12 Suppl 5: S11.
25. Huang LC, Wu X, Chen JY (2013) Predicting adverse drug reaction profiles by integrating protein interaction networks with drug structures. Proteomics 13: 313-324.
26. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242.
27. Yang L, Chen J, He L (2009) Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome. PLoS Comput Biol 5: e1000441.
28. Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, et al. (2012) Large-scale prediction and testing of drug activity on side-effect targets. Nature 486: 361-367.
29. Wallach I, Jaitly N, Lilien R (2010) A structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathways. PLoS One 5: e12063.
30. Xie L, Li J, Xie L, Bourne PE (2009) Drug Discovery Using Chemical Systems Biology: Identification of the Protein-Ligand Binding Network to Explain the Side Effects of CETP Inhibitors. PLoS Computational Biology 5(5): e1000387.
31. Reardon S (2013) Project ranks billions of drug interactions. Nature 503: 449- 450.
32. Kirkpatrick P, Ellis C (2004) Chemical space. Nature 432: 823-823.
33. Zhang X, Wong SE, Lightstone FC (2013) Message passing interface and multithreading hybrid for parallel molecular docking of large databases on petascale high performance computing machines. J Comput Chem 34: 915-927.
34. Huang N, Shoichet BK, Irwin JJ (2006) Benchmarking sets for molecular docking. J Med Chem 49: 6789-6801.
35. Zhang X, Wong SE, Lightstone FC (2014) Toward Fully Automated High Performance Computing Drug Discovery: A Massively Parallel Virtual Screening Pipeline for Docking and Molecular Mechanics/Generalized Born Surface Area Rescoring to Improve Enrichment. J Chem Inf Model 54: 324- 337.
36. FDA (2014) Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. http://www.accessdata.fda.gov/scripts/Cder/ob/default.cfm.
37. Brown EG, Wood L, Wood S (1999) The medical dictionary for regulatory activities (MedDRA). Drug Saf 20: 109-117.
38. Nilmeier JP, Kirshner DA, Wong SE, Lightstone FC (2013) Rapid catalytic template searching as an enzyme function prediction procedure. PLoS One 8: e62535.
39. Kirshner DA, Nilmeier JP, Lightstone FC (2013) Catalytic site identification-a web server to identify catalytic site structural matches throughout PDB. Nucleic Acids Res 41: W256-W265.
40. Halgren TA (2009) Identifying and Characterizing Binding Sites and Assessing Druggability. Journal of Chemical Information and Modeling 49: 377-389.
41. Mysinger MM, Carchia M, Irwin JJ, Shoichet BK (2012) Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking. J Med Chem 55: 6582-6594.
42. Wang RX, Lu YP, Wang SM (2003) Comparative evaluation of 11 scoring functions for molecular docking. J Med Chem 46: 2287-2303.
43. Warren GL, Andrews CW, Capelli AM, Clarke B, LaLonde J, et al. (2006) A critical assessment of docking programs and scoring functions. J Med Chem 49: 5912-5931.
44. Richards FM (1977) Areas, volumes, packing and protein structure. Annu Rev Biophys Bioeng 6: 151-176.
45. Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE (1982) A geometric approach to macromolecule-ligand interactions. J Mol Biol 161: 269-288.
46. Case DA, Cheatham TE 3rd, Darden T, Gohlke H, Luo R, et al. (2005) The Amber biomolecular simulation programs. J Comput Chem 26: 1668-1688.
47. Case DA, Darden TA, Cheatham TE, Simmerling CL, Wang J, et al. (2012) AMBER12 and AMBERTOOLS13. San Francisco, CA: Universty of California San Francisco.
48. Mongan J, Simmerling C, McCammon JA, Case DA, Onufriev A (2007) Generalized Born Model with a Simple, Robust Molecular Volume Correction. J Chem Theory Comput 3: 156-169.
49. Onufriev A, Bashford D, Case DA (2004) Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins: Structure, Function, and Bioinformatics 55: 383-394.
50. Zhang X, Gibbs AC, Reynolds CH, Peters MB, Westerhoff LM (2010) Quantum mechanical pairwise decomposition analysis of protein kinase B inhibitors: validating a new tool for guiding drug design. J Chem Inf Model 50: 651-661.
51. Thompson DC, Humblet C, Joseph-McCarthy D (2008) Investigation of MMPBSA rescoring of docking poses. J Chem Inf Model 48: 1081-1091.
52. Guimaraes CR, Cardozo M (2008) MM-GB/SA rescoring of docking poses in structure-based lead optimization. J Chem Inf Model 48: 958-970.
53. Rastelli G, Rio AD, Degliesposti G, Sgobba M (2010) Fast and accurate predictions of binding free energies using MM-PBSA and MM-GBSA. Journal of Computational Chemistry 31: 797-810.
54. Moitessier N, Englebienne P, Lee D, Lawandi J, Corbeil CR (2008) Towards the development of universal, fast and highly accurate docking/scoring methods: A long way to go. Br J Pharmacol 153 Suppl 1: S7-S26.
55. Raha K, Peters MB, Wang B, Yu N, Wollacott AM, et al. (2007) The role of quantum mechanics in structure-based drug design. Drug Discov Today 12: 725-731.
56. Wang R, Lu Y, Wang S (2003) Comparative Evaluation of 11 Scoring Functions for Molecular Docking. Journal of Medicinal Chemistry 46: 2287-2303.
57. Sousa SF, Fernandes PA, Ramos MJ (2006) Protein-ligand docking: current status and future challenges. Proteins 65: 15-26.
58. Yang Y, Lightstone FC, Wong SE (2013) Approaches to efficiently estimate solvation and explicit water energetics in ligand binding: The use of water map. Expert Opinion on Drug Discovery 8: 277-287.
59. Wong SE, Lightstone FC (2011) Accounting for water molecules in drug design. Expert Opin Drug Discov 6: 65-74.
60. Tibshirani R (1996) Regression Shrinkage and Selection via the Lasso. Journal of the Royal Statistical Society Series B 58: 267-288.
61. Wu TT, Chen YF, Hastie T, Sobel E, Lange K (2009) Genome-wide association analysis by lasso penalized logistic regression. Bioinformatics 25: 714-721.
62. Friedman J, Hastie T, Tibshirani R (2010) Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw 33: 1-22.
63. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100: 9440-9445.
64. Bonferroni C (1935) Il calcolo delle assicurazioni su gruppi di teste. Studi in Onore del Professore Salvatore Ortu Carboni. Rome, Italy. pp. 13-60.
65. Sousa SF, Ribeiro AJM, Coimbra JTS, Neves RP, Martins SA, et al. (2013) Protein-Ligand Docking in the New Millennium - A Retrospective of 10 Years in the Field. Current Medicinal Chemistry 20: 2296-2314.
66. Lenselink EB, Beuming T, Sherman W, van Vlijmen HW, Ijzerman AP (2014) Selecting an Optimal Number of Binding Site Waters to Improve Virtual Screening Enrichments Against the Adenosine A2A Receptor. J Chem Inf Model 54: 1737-1746.
67. Beuming T, Farid R, Sherman W (2009) High-energy water sites determine peptide binding affinity and specificty of PDZ domains. Protein Sc 18: 1609- 1619.
68. Poongavanam V, Steinmann C, Kongsted J (2014) Inhibitor Ranking through QM Based Chelation Calculations for Virtual Screening of HIV-1 RNase H Inhibition. PLOS ONE 9(6): e98659. doi:10.1371/journal.pone.0098659.
69. Englebienne PF, Fiaux H, Kuntz DA, Corbeil CR, Gerber-Lemaire S, et al. (2007) Evaluation of docking programs for predicting binding of Golgi alpha- mannosidase II inhibitors: A comparison with crystallography. Proteins 69: 160- 176.
70. Brylinski M, Skolnick J (2011) FINDSITE-metal: integrating evolutionary information and machine learning for structure-based metal-binding site prediction at the proteome level. Proteins 79: 735-751.
71. Chimal-Ramirez GK, Espinoza-Sanchez NA, Utrera-Barillas D, Benítez-Bribiesca L, Velázquez JR, et al. (2013) MMP1, MMP9, and COX2 Expressions in Promonocytes Are Induced by Breast Cancer Cells and Correlate with Collagen Degradation, Transformation-Like Morphological Changes in MCF- 10A Acini, and Tumor Aggressiveness. BioMed Research International, doi:10.1155/2013/279505.
72. Li X, Tai HH (2013) Thromboxane A2 receptor-mediated release of matrix metalloproteinase-1 (MMP-1) induces expression of monocyte chemoattractant protein-1 (MCP-1) by activation of protease-activated receptor 2 (PAR2) in A549 human lung adenocarcinoma cells. Molecular Carcinogenesis doi: 10.1002/mc.22020.
73. Lin Y, Wang JF, Gao GZ, Zhang GZ, Wang FL, et al. (2013) Plasma levels of tissue inhibitor of matrix metalloproteinase-1 correlate with diagnosis and prognosis of glioma patients. Chin Med J (Engl) 126: 4295-4300.
74. Korematsu S, Ohta Y, Tamai N, Takeguchi M, Goto C, et al. (2012) Cell distribution differences of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in patients with Kawasaki disease. Pediatr Infect Dis J 31: 973-974.
75. Chen XL, Li L, Zhang YJ (2011) [Regulatory role of Syk gene on vascular endothelial growth factor C expression in breast cancer]. Zhonghua Bing Li Xue Za Zhi 40: 805-809.
76. Zhang X, Shrikhande U, Alicie BM, Zhou Q, Geahlen RL (2009) Role of the protein tyrosine kinase Syk in regulating cell-cell adhesion and motility in breast cancer cells. Mol Cancer Res 7: 634-644.
77. Repana K, Papazisis K, Foukas P, Valeri R, Kortsaris A, et al. (2006) Expression of Syk in invasive breast cancer: correlation to proliferation and invasiveness. Anticancer Res 26: 4949-4954.
78. Layton T, Stalens C, Gunderson F, Goodison S, Silletti S (2009) Syk Tyrosine Kinase Acts as a Pancreatic Adenocarcinoma Tumor Suppressor by Regulating Cellular Growth and Invasion. The American Journal of Pathology 175: 2625- 2636.
79. Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, et al. (2012) Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer 131: 911-923.
80. Wilgenhof S, Morlion V, Seghers AC, Du Four S, Van der linden E, et al. (2012) Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti- CTLA-4 monoclonal antibody and selective BRAF inhibitor. Anticancer Res 32: 1355-1359.
81. Hattori N, Niimi T, Sato S, Achiwa H, Maeda H, et al. (2005) Cytotoxic Tlymphocyte antigen 4 gene polymorphisms in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 22: 27-32.
82. Romeo G, Frangioni JV, Kazlauskas A (2004) Profilin acts downstream of LDL to mediate diabetic endothelial cell dysfunction. FASEB J 18: 725-727.
83. Stuijver DJ, van Zaane B, Romualdi E, Brandjes DP, Gerdes VE, et al. (2012) The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: A systematic review and meta-analysis. Thromb Haemost 108: 1077- 1088.
84. Kim HW, Rapoport SI, Rao JS (2010) Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol Dis 37: 596-603.
85. Gasso P, Mas S, Molina O, Lafuente A, Bernardo M, et al. (2014) Increased susceptibility to apoptosis in cultured fibroblasts from antipsychotic-naive firstepisode schizophrenia patients. J Psychiatr Res 48: 94-101.
86. Konstandin MH, Aksoy H, Wabnitz GH, Volz C, Erbel C, et al. (2009) Beta2- integrin activation on T cell subsets is an independent prognostic factor in unstable angina pectoris. Basic Res Cardiol 104: 341-351.
87. Pere JJ, Chaumet-Riffaud D (1990) [Clozapine and resistant schizophrenia]. Encephale 16: 143-145.